Zylorion appoints members to newly formed science and digital health advisory committees

CALGARY, AB, December 8, 2021 / PRNewswire / – PsiloTec Health Solutions Inc., operating as Zylorion Health, (“Zylorion” or the “Society”), an innovator focused on mental health care and psychedelic therapy, is pleased to announce the establishment of the Company’s Scientific Advisory Board and Digital Health Advisory Board (collectively the “Committees”), and the appointment five highly distinguished members on the committees. “We are honored to work with this talented group of renowned experts in their respective fields of study. These committee members bring highly relevant, diverse and credible expertise to Zylorion, and their contributions will certainly add immeasurable value to guide and support the execution of our strategic goals, ”commented Dr. Pierre Silverstone, Chief Executive Officer and Director.

Zylorion logo (CNW Group / Zylorion Health)

Scientific advisory committee

Dr. Allan Young, chairman of the committee (London, United Kingdom) is the Chief of Academic Psychiatry and Chair of Mood Disorders at the King’s College Institute of Psychiatry, Psychology and Neuroscience London, United Kingdom. Dr. Young is a leading expert in serious psychiatric illness and is recognized by Thomson Reuters as one of the world’s foremost scientific minds in the field of psychiatry and psychology. He has over 600 peer-reviewed publications and has written several books on psychopharmacology and affective disorders. Dr Young is a member of several editorial boards and a member of numerous professional and scientific societies. Dr Young is Past President of the International Society for Affective Disorders, Past President of the British Psychopharmacological Association and Past Chairman of the Special Committee on Psychopharmacology of the Royal College of Psychiatrists. Dr Young and his colleagues at King’s College London are actively involved in psychedelic research.

Dr. Trisha suppes (Palo Alto, United States) is professor of psychiatry and behavioral sciences, and member of Bio-X, Stanford University interdisciplinary institute of biological sciences. Dr. Suppes served as Chairman of the US Department of Defense, of the Veterans Affairs (“VA”) Guidelines for Bipolar Disorder and of the Bipolar Module of the Texas Medication Algorithm Project. In addition, Dr. Suppes is also Director of the Exploratory Therapy Laboratory and founder of the Bipolar and Depression Research Program of the VA Palo Alto Healthcare System. Dr. Suppes has published over 250 publications and received numerous awards and recognitions for her contributions to her field. Dr Suppes is ranked among the foremost scientific minds in psychiatry and psychology, Thomson Reuters Highly Cited Researchers

Dr. Pierre Chue (Edmonton, CAN) has extensive experience in clinical psychopharmacology, including as founder and director of the clinical trials and research program, University of Alberta. Dr. Chue has participated in more than 50 national and international clinical trials in the areas of mood and anxiety disorders as well as addictions. As a professor in the Department of Psychiatry of the University of Alberta, he is an active clinician and researcher at the Integrative Health Institute, the Center of Excellence for Real-World Clinical Outcomes, the Neuroscience and Mental Health Institute, and the Campus Alberta Neuroscience. Having obtained specialist qualifications in psychiatry from the UK, Canada, and in the United States, Dr. Chue has authored or co-authored over 150 articles and abstracts in peer-reviewed medical journals, book chapters, and scientific symposia. Dr Chue has published several Cochrane Reviews and contributed to national guidelines and has given over 600 presentations as a visiting professor and / or guest contributor at major psychiatric conferences, academia and in the media.

Digital Health Advisory Committee

Dr. Walter Green Leaf, chairman of the committee (Palo Alto, United States) is a neuroscientist and medical technology developer working at Stanford University. With over three decades of research and development experience, Dr Greenleaf is considered a leading authority in the field of digital medicine and medical virtual reality technology. Dr Greenleaf is currently focused on the development of computer-assisted clinical products, with particular emphasis on the application of virtual reality and digital health technology to treat areas of behavioral and physical medicine such as PTSD, anxiety disorders, depression, traumatic brain injury and stroke, addictions, and autism spectrum disorders. Dr Greenleaf is currently Distinguished Visiting Fellow at Stanford University MediaX program, guest researcher at Stanford University Virtual Human Interaction Lab, and the Director of Technology Strategy at University of Colorado National Center for Mental Health Innovation. In addition to his research at Stanford UniversityDr. Greenleaf has played a leading role in several pioneering medical product companies, most notably as Scientific Director of Pear Therapeutics, a biotechnology company that develops digital prescription therapies to treat diseases and improve the effectiveness of pharmaceuticals. and as Senior Vice President of Strategy & Corporate Affairs at MindMaze, a global leader in brain health technology. Dr Greenleaf serves on the board of directors of Brainstorm, the Stanford laboratory for innovation and entrepreneurship in brain health; for Cognitive Leap, a company that develops mental health solutions for children; and for Sine Wave, the developer of Sine Space, a multi-user online virtual world platform. Dr Greenleaf is currently a technology and neuroscience consultant to several start-up medical product companies.

Ms. Beth RogozinskI (San Francisco, United States) is a serial entrepreneur, technology innovator and business strategist with a background in digital medicine and medical devices. Ms. Rogozinski has worked in hardware, software and services with leading technology companies including Silicon Graphics, Macromedia and digital agency Circle. Ms. Rogozinski has also founded digital game and application development companies including Signal 2 Productions, Match Factor and D2S Games. Ms. Rogozinski has produced and published over a dozen software applications focused on health and wellness. As Product Manager at Pear Therapeutics Inc. (“Pear”), Ms. Rogozinski led the development of Pear’s first clinical products and the submission of the De Novo project. 510k to the United States Food and Drug Administration (the “FDA”). Pear’s ReSET ™ was cleared by the FDA in 2017 as the very first digital prescription therapy. Ms. Rogozinski is a director and advisor to a number of start-ups and high-growth accelerators, and has consulted with numerous health and innovation centers, such as Stanford University, UnitedHealth Group and the National Mental Health Innovation Center. Ms. Rogozinski is currently President and CEO of Oncoustics, an innovative artificial intelligence solutions company that creates low-cost, non-invasive surveillance, diagnostics and treatment for diseases with high unmet clinical needs.

“We are delighted to be working with such a high caliber group of talented individuals who share our passion and our quest to bring relief and restore mental well-being,” said Dr. Silverstone.

The committees will play an active and integral role in guiding and advising the strategic direction of Zylorion’s clinical research focused on the development of psychedelic-based compounds and therapy programs based on the Company’s proprietary technology.

About Zylorion
Zylorion is a biopharmaceutical company engaged in the development and delivery of integrated mental health therapies to treat psychological and neurological mental health issues. Zylorion is focused on the research, development and commercialization of psychedelic-based compounds coupled with therapeutic treatment programs targeting a continuum of mental health problems, such as MDD (major depressive disorder), TRD (depression resistant to treatment), PTSD (post-traumatic stress disorder). , general depression, anxiety disorders and a number of addictive tendencies. Zylorion aims to leverage cutting-edge technologies to support the scalability and accessibility of its integrated therapy programs in its mission to empower people with mental health challenges to thrive.

Caution regarding forward-looking statements
This press release contains statements that constitute forward-looking information (“forward-looking information”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as of the date of this press release. Any statement that deals with predictions, expectations, beliefs, plans, projections, goals, assumptions, events or future performance (often but not always using expressions such as “expects “Or” does not expect “,” is expected “,” anticipates “or” does not anticipate “,” plans “,” budget “,” planned “,” plans “,” estimates “,” believes “or “intends” or variations of these words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “could” or “?



View original content to download multimedia:https://www.prnewswire.com/news-releases/zylorion-appoints-members-to-newly-formed-scientific-and-digital-health-advisory-committees-301439824.html

SOURCE Zylorion Health

Source link

Comments are closed.